The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
 
Anca Chelariu- Raicu
No Relationships to Disclose
 
Charles F. Levenback
No Relationships to Disclose
 
Brian M. Slomovitz
Consulting or Advisory Role - Agenus; AstraZeneca; Clovis Oncology; Genentech; Incyte; Tesaro
 
Diane C. Bodurka
No Relationships to Disclose
 
David Marc Gershenson
Stock and Other Ownership Interests - Biogin; Celgene; Johnson & Johnson
Consulting or Advisory Role - Genentech
Research Funding - Novartis
Patents, Royalties, Other Intellectual Property - Royalties from Elsevier as book editor; Royalties from UpToDate for authorship
 
Robert L. Coleman
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche; Genmab; Immunogen; Novocure; Oncolytics; OncoMed; OncoSec; Sotio; Tesaro
Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group